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Abstract
Objectives: To determine whether coadjuvant antineoplastic treatment can influence the number and size of bone 
exposures among patients with intravenous bisphosphonate-related osteonecrosis of the jaws (iBRONJ), and to 
analyze the buccodental condition of these patients.
Material and methods: The study sample comprised 67 patients with iBRONJ, 53 patients without iBRONJ receiv-
ing treatment with intravenous bisphosphonates, and 36 healthy subjects. In all three groups, measurements were 
made of the CAO index and of resting whole saliva and stimulated whole saliva. In the patients with iBRONJ, the 
size (cm) and number of bone exposures were recorded. The data obtained were subjected to analysis of variance 
(ANOVA), the Mann-Whitney U-test, and multivariate logistic regression analysis. 
Results: A total of 57.6% of the patients presented single bone exposure, 25.4% presented two, and 17% more 
than two exposures. The mean exposure size was 2.3±1.9 cm. Neither the bivariate analysis nor the multivariate 
multiple regression analysis found coadjuvant antineoplastic treatment to exert a statistically significant effect 
upon the number and size of bone exposures. On the other hand, there were statistically significant differences 
among the three study groups in relation to the CAO index (p=0.02) and the number of missing teeth (p=0.00). 
The resting whole saliva and stimulated whole saliva levels were similar in the three groups, though the patients 
with osteonecrosis of the jaws showed comparatively lower SWS levels.
Conclusions: Coadjuvant antineoplastic treatment alone appears to exert no influence upon the size and number of bone 
exposures in iBRONJ. The patients with this disease show a higher CAO index and a larger number of missing teeth.
Key words: Osteonecrosis of the jaws, bisphosphonates, bone exposure, CAO index, resting whole saliva, stimu-
lated whole saliva.
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Introduction
Osteonecrosis of the jaws is a form of chronic and 
slow-evolving osteomyelitis with no tendency towards 
spontaneous healing. The most widely known clini-
cal form is osteoradionecrosis, a form of osteomyelitis 
associated to radiotherapy (1). Since the year 2003, a 
new form of osteonecrosis has been described, referred 
to as bisphosphonate-related osteonecrosis of the jaws 
(BRONJ), which is defined as the presence of necrotic 
bone exposed within the oral cavity for over 6-8 weeks 
in patients receiving or who have received treatment 
with bisphosphonates (BPs), and who have not under-
gone radiotherapy in the cervicofacial region (2,3). In-
stead of necrotic bone exposure, the disease in some 
cases is characterized by mucosal ulceration and symp-
toms - usually pain and suppuration, and even orosi-
nusal communications and pathological fractures. This 
condition is also regarded as bisphosphonate-related 
osteonecrosis of the jaws (4,5).
The pathogenesis of BRONJ is not fully understood. The 
most widely accepted hypothesis refers to the existence 
of an alteration in physiological bone remodeling second-
ary to intense inhibition of the osteoclasts. Bisphospho-
nates inhibit osteoclast reabsorption activity by blocking 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), 
the enzyme in charge of osteoclast protein prenylation 
(6). The appearance of cases of BRONJ in patients receiv-
ing treatment with denosumab (7), an anti-RANK ligand 
monoclonal antibody, confirms the theory that osteoclast 
inhibition is the triggering event underlying BRONJ (8). 
The BPs have also been attributed with certain antiang-
iogenic and antitumor effects (9).
BRONJ has very characteristic clinical manifestations 
that allow it to be easily identified from first contact 
with the patient (10).
Major risk factors for BRONJ are the potency and duration 
of intravenous BP treatment, particularly with zoledronic 
acid, and dentoalveolar surgery – fundamentally extrac-
tions (11). Other treatments commonly administered to 
cancer patients, such as corticosteroids, immunosuppres-
sors and hormone therapy, may also increase the risk of 
suffering BRONJ (12). It has been suggested that certain 
polymorphisms of the CYP2C8 gene could induce a de-
gree of genetic susceptibility towards BRONJ, though this 
finding has not been confirmed by other studies (13).
 The great majority of authors and expert panels agree 
on the importance of preventing BRONJ through the es-
tablishment and maintenance of adequate buccodental 
health (2,3,14,15). A rapid and simple method for as-
sessing buccodental health is the CAO index, described 
by Klein, Palmer and Knutson (16), and adopted by the 
World Health Organization (WHO) for the conduction 
of oral health surveys, with the measurement of present 
and past caries in an individual or population.
Considering the natural tendency of intravenous BRONJ 
lesions to progress and spread over time (Fig. 1), the 
Fig. 1. Images of one same patient with multiple bone exposure sites, corresponding to intravenous bisphosphonate-
related osteonecrosis of the jaws. 
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first objective of the present study was the evaluation 
of whether coadjuvant antineoplastic treatment such as 
corticosteroids, thalidomide, interferon and hormones 
can influence the number and size of bone exposures. 
On the other hand, we have only found one publica-
tion comparing the buccodental conditions of patients 
receiving treatment with intravenous bisphosphonates 
versus those of patients who have already developed os-
teonecrosis of the jaws (17). Our second objective there-
fore has been the analysis and comparison of buccoden-
tal health and of the resting whole saliva and stimulated 
whole saliva levels in a group of patients with iBRONJ 
versus a group of patients administered BP via the in-
travenous route but who do not present BRONJ, and un 
control group of healthy patients.
Material and Methods
All patients were seen in the Department of Stomatol-
ogy and Maxillofacial Surgery (Valencia University 
General Hospital, Valencia, Spain) during the period be-
tween March 2006 and July 2009, in collaboration with 
the Departments of Hematological Oncology of Valen-
cia University Clinic Hospital, La Fe University Hospi-
tal and Valencia University General Hospital (Valencia, 
Spain). Informed consent was obtained in all cases, and 
the study was approved by the Clinical Research Ethics 
Committee of Valencia University General Hospital.
The study sample consisted of 156 patients, 105 women 
(67.3%) and 51 men (32.7%), with a mean age (± SD) of 
62.3±10.9 years. Three groups were established:
- Group A: 67 patients administered intravenous bi-
sphosphonates and who developed iBRONJ: 39 women 
and 28 men, with a mean age of 63.7 ± 11.6 years.
- Group B: 53 patients administered intravenous bi-
sphosphonates but without BRONJ: 37 women and 16 
men, with a mean age of 60.3±10.9 years.
- Group C: 36 healthy controls matched for age and gen-
der to the other two groups. 
Data were collected referred to the background ma-
lignancy, iBRONJ and buccodental condition. For the 
clinical exploration we used an intraoral mirror and 
exploratory probe. The diagnosis of BRONJ was based 
on the corresponding clinical and radiological criteria 
(2,3,12). Samples of resting whole saliva (RWS) and 
stimulated whole saliva (SWS) were collected. Saliva 
measurement was not possible in 28 patients in group 
 
Malignancy BP administered Time on BP 
(months) MM* `BC? Zol? Pam? Zol+Pam 
Group A 43.3% 41.8% 66.2% 2% 31.8% 32.2±17.6? 
Group B 49% 41.2% 100% - - 22.5±10.8? 
Table 1. Comparison between groups A and B referred to type of primary neoplasm, type of bisphos-
phonate (BP) administered, and duration of treatment.
* MM: Multiple myeloma ♠ BC: Breast cancer ● Zol: Zoledronic acid ♦ Pam: Pamidronate ♣ Mean ± SD.
A. In the remaining 128 patients, saliva samples were 
collected as described below: 
Sampling was carried out early in the morning in the 
dental clinic, under fasting conditions or after at least 
two hours without oral ingestion of any kind. Before 
collecting the saliva sample, the patients were instruct-
ed to rinse the oral cavity with desalinized water and 
then expel the water. The RWS sample was collected 
first, instructing the patients to expel the saliva accumu-
lated in the floor of the mouth every 60 seconds over a 
period of 5 minutes. Emphasis was placed on the impor-
tance of not swallowing the saliva produced. The saliva 
was collected through a glass funnel in a 15-ml, millim-
etered Falcon-type tube (VWR Internacional Eurolab, 
S.L., Barcelona, Spain). Two minutes after completing 
collection of the resting sample, the SWS sample was 
collected. Paraffin blocks measuring 1.5 x 1 x 0.5 cm in 
size were used to this effect (CRT Paraffin Vivadent®. 
Ivoclar Vivadent AG, Liechtenstein), instructing the 
patients to keep a uniform chewing rhythm throughout 
the procedure (average of 70 mastications/minute), and 
to avoid swallowing the saliva produced. In contrast to 
the sampling of resting saliva, the saliva produced in 
the first two minutes was discarded, with collection of 
the saliva generated in the subsequent 5 minutes, using 
the same system as in the case of RWS sampling. The 
amount of saliva obtained under both resting and stimu-
lated conditions was then measured, expressed as ml of 
saliva/5 minutes.
The predominant background malignancy in groups A 
and B was multiple myeloma (45.8%), followed by breast 
(41.5%), prostate (9.3%), lung (1.7%), kidney (0.8%) and 
bladder cancer (0.8%). The most frequently administered 
bisphosphonate was zoledronic acid (97.5%). The patients 
in group B received only zoledronic acid, while in group 
A, 66.2% of the patients received zoledronic acid, 31.8% 
received zoledronic acid associated to pamidronate, and 
2% received only pamidronate (Table 1).
The data obtained were analyzed using the SPSS ver-
sion 15.0 statistical package (SPSS Inc., Chicago IL, 
USA). A descriptive study was made, calculating the 
mean, standard deviation and frequency distribution. 
The comparative study in turn was based on analysis 
of variance (ANOVA), the Mann-Whitney U-test, and 
multivariate logistic regression analysis. Statistical sig-
nificance was considered for p<0.05.
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Fig. 2. Number of bone exposure sites recorded in the patients with intravenous bisphosphonate-related osteonecrosis of the jaws.
Results
-Number and size of bone exposures
A total of 57.6% of the patients presented single bone 
exposure, 25.4% presented two, 5.1% three, 10.2% four, 
and 1.7% presented 8 exposures (Fig. 2). The mean ex-
posure size was 2.3±1.9 cm (median 2 cm). �n the bi-
variate analysis, none of the coadjuvant antineoplastic 
treatments considered (corticosteroids, thalidomide, 
interferon and hormones) were significantly related to 
either the size or number of exposures (Table 2). �n turn, 
in none of the logistic regression analysis models was 
Variables
Mann-Whitney U-test results 
p-value 
Number of 
exposures 
Exposure size 
Corticosteroids 0.118  0.189 
Thalidomide 0.991  0.991 
Interferon 0.81  0.121  
Hormones 0.07 0.78 
Table 2. Results of the bivariate analysis (Mann-Whitney U-
test) of the number and size of bone exposures.
coadjuvant antineoplastic treatment able to explain and 
predict the total size or number of exposures.
-CAO index
The mean CAO index (ICAO) for the total sample was 
14.7. In group A (BRONJ) the mean ICAO was 16.8, ver-
sus 12.5 in group B (without BRONJ) and 13.4 in group 
C (control). The difference in ICAO distribution in the 
three groups was statistically significant (p=0.02). 
On analyzing �CAO more in detail, the global mean 
number of caried teeth was found to be 1.6, with indi-
vidualized values of 1.7, 1.8 and 0.8 for groups A, B and 
C, respectively. These differences were not statistically 
significant (p>0.05). The global mean number of miss-
ing teeth was 10.7. Statistically significant differences 
were observed in the mean number of missing teeth 
among the three study groups: 14.3 in group A, 6.8 in 
group B and 9.1 among the controls (group C) (p=0.00). 
Lastly, the global mean number of filled teeth was 3.4. 
No statistically significant differences were observed in 
the mean number of filled teeth among the groups: 3.1 
in group A, 3.8 in group B and 3.4 in group C (p>0.05). 
The results referred to the CAO index and its variables 
are summarized in table 3.
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Group A Group B Group C ANOVA Significance 
RWS (ml/5’) 1.3 1.1 1 F=0.954 p>0.05 
SWS (ml/5’) 2.7 3.2 3.3 F=1.2 p>0.05 
Table 4. Mean values in each study group corresponding to resting whole saliva (RWS) and 
stimulated whole saliva (SWS).
 Group A Group B Group C ANOVA Significance 
CAO index 16.8 12.5 13.4 F=4.032 p=0.02 
C? 1.7 1.8 0.8 F=1.117 p>0.05 
A? 14.3 6.8 9.1 F=11.508 p=0.00 
O? 3.1 3.8 3.55 F=0.727 p>0.05 
Table 3. Mean values in each study group corresponding to the 
CAO index and its variables.
♠ C: Number of caried teeth ● A: Number of missing teeth ♦ O: 
Number of filled (obturated) teeth.
-Resting whole saliva (RWS) and stimulated whole sa-
liva (SWS)
The global mean amount of RWS obtained in the 128 pa-
tients was 1.1 ml saliva/5 minutes. In group A (BRONJ) 
the mean amount was 1.3 ml/5 minutes, versus 1.1 
ml/5 minutes in group B (without BRONJ), and 1 ml/5 
minutes in group C (controls). In turn, the global mean 
amount of SWS obtained was 3.1 ml saliva/5 minutes. 
In group A the mean amount was 2.7 ml/5 minutes, ver-
sus 3.2 ml/5 minutes in group B, and 3.3 ml/5 minutes 
in group C. No statistically significant differences were 
found on comparing the mean amounts of RWS and 
SWS obtained in each group (p>0.05) (Table 4).
Discussion
The two main disorders associated to prolonged bisphos-
phonate therapy are BRONJ and pathological femoral 
fracture (18). The apparently exclusive location of BRONJ 
in the oral cavity, and specifically in jaw bone, appears to 
be related to the fact that this bone has a high turnover 
rate, which favors the accumulation of large amounts of 
bisphosphonates (19). The main risk factors for BRONJ 
are prolonged intravenous bisphosphonate therapy in-
volving high-potency drugs, dentoalveolar surgical pro-
cedures, poorly fitting dental prostheses and intraoral 
trauma (20). Other factors that have also been related to 
BRONJ are chemotherapy, antiangiogenic drugs such as 
thalidomide, diabetes mellitus, corticosteroids, genetic 
susceptibility and deficient oral hygiene (21).
The different published series on osteonecrosis of the 
jaws generally do not describe the number or size of the 
bone exposure sites. At most, mention is made of the 
location of exposure in the upper or lower jaw, or both 
(22,23). We have found only three studies, published by 
Bagán et al. (1,10,11), in which express mention is made 
of the number of areas of exposed bone and their global 
mean size. 
More than one-half of our patients (57.6%) presented 
a single bone exposure site, while 25.4% had two and 
17% presented more than two exposures. This latter 
subgroup included patients with up to 8 iBRONJ expo-
sure sites. According to Thumbigere-Math et al. (24), 
80% of all spontaneously manifesting iBRONJ lesions 
measure 1 cm or less in diameter, and a little over one-
half of the lesions appearing after a dental procedure 
(56.3%) have these same dimensions (i.e., 1 cm or less). 
�n our series, 50% of the patients presented a lesion size 
of between 1-3 cm, though there were two individuals 
with an unusually large lesion (7 cm), and one patient 
with an extreme lesion size of 10 cm. �t should be un-
derscored that on the basis of our findings, coadjuvant 
antineoplastic treatment alone exerted no influence 
upon the size and number of osteonecrosis areas in the 
context of iBRONJ.
A greater CAO index and a larger number of missing 
teeth were found in the patients with iBRONJ (p<0.05). 
The study published by Carmagnola et al. (17), which did 
not include a control group, reported no statistically sig-
nificant differences in either the CAO index or in residual 
periodontal support between 20 patients with iBRONJ and 
19 patients subjected to intravenous bisphosphonates with-
out BRONJ. In that same publication, 50% of the patients 
with iBRONJ had a history of tooth extraction, versus 
26.3% of the subjects without BRONJ. In our series, 73.1% 
of the patients in group A (BRONJ) had undergone tooth 
extraction, versus only 9.4% of those in group B (without 
BRONJ). These figures are similar to those recorded in the 
first published series on osteonecrosis of the jaws, in which 
77% of the patients had undergone dental extraction (23). 
Likewise, Boonyapakorn et al. (25), in a study of 80 pa-
tients with BRONJ, found 77% of them to have a history of 
extraction. We found no statistically significant differences 
among the three groups in terms of the number of caried 
teeth or the number of filled teeth (p>0.05), though both 
caried and filled teeth were more prevalent in group B.
The RWS levels were practically the same in all three 
groups (p>0.05). Certain differences were observed in the 
case of SWS, with lesser levels among the patients with 
BRONJ – though statistical significance was not reached. 
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At the time of intraoral exploration and collection of the 
saliva samples, 94% of the patients with BRONJ were 
receiving chemotherapy – a percentage that dropped to 
68% in the case of group B (without BRONJ). These 
data could partially account for the observed differ-
ences among the study groups as regards buccodental 
condition. The fact that the patients with BRONJ had a 
longer duration of treatment with bisphosphonates, and 
the concomitant administration of chemotherapy, could 
have influenced the existence of oral cavity disorders 
such as diminished salivary gland function, increased 
susceptibility to fungal, viral and bacterial infections, 
and pro-pathogenic changes in the oral microflora 
(26,27). The greater number of missing teeth among the 
patients in group A might be related to the above.
A growing number of studies underscore the beneficial 
effects of oral health prevention and maintenance strat-
egies in patients programmed for or who are already re-
ceiving intravenous bisphosphonate therapy (28,29). In 
relation to BRONJ, we feel that studies addressing the 
buccodental health of these patients are required.
Conclusion
Coadjuvant antineoplastic treatment alone appears to 
exert no influence upon the size and number of exposed 
bone sites in the context of i.v. BRONJ – the patients 
with this disease in turn showing a comparatively great-
er CAO index and a larger number of missing teeth.
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